[{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"National Heart, Lung, and Blood Institute | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ramipril","moa":"Angiotensin-converting enzyme","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alabama at Birmingham \/ National Heart, Lung, and Blood Institute | AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"University of Alabama at Birmingham \/ National Heart, Lung, and Blood Institute | AstraZeneca"},{"orgOrder":0,"company":"Dexa Medica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDONESIA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"DLBS1449","moa":"Blood glucose level","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dexa Medica \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Dexa Medica \/ Undisclosed"},{"orgOrder":0,"company":"Prisma Health-Midlands","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Omega-3-Acid Ethyl Esters 90","moa":"DGAT||steroids (androgens","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Prisma Health-Midlands","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Prisma Health-Midlands \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Prisma Health-Midlands \/ Undisclosed"},{"orgOrder":0,"company":"Dexa Medica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDONESIA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"DLBS1033","moa":"Fibrinolytic protein","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dexa Medica \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Dexa Medica \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Supaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Supaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Supaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. \/ The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","highestDevelopmentStatusID":"9","companyTruncated":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. \/ The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School"},{"orgOrder":0,"company":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","sponsor":"Shanghai 6th People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Supaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. \/ Shanghai 6th People's Hospital","highestDevelopmentStatusID":"9","companyTruncated":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. \/ Shanghai 6th People's Hospital"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Beta Bionics | Zealand Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2019","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Beta Bionics | Zealand Pharma","highestDevelopmentStatusID":"9","companyTruncated":"Massachusetts General Hospital \/ Beta Bionics | Zealand Pharma"},{"orgOrder":0,"company":"University Hospital, Caen","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Exenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"University Hospital, Caen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University Hospital, Caen \/ Eli Lilly","highestDevelopmentStatusID":"9","companyTruncated":"University Hospital, Caen \/ Eli Lilly"},{"orgOrder":0,"company":"Centre Hospitalier Universitaire de Besancon","sponsor":"AstraZeneca | Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Exenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Centre Hospitalier Universitaire de Besancon","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Hospitalier Universitaire de Besancon \/ AstraZeneca | Eli Lilly","highestDevelopmentStatusID":"9","companyTruncated":"Centre Hospitalier Universitaire de Besancon \/ AstraZeneca | Eli Lilly"},{"orgOrder":0,"company":"Radboud University Medical Center","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"NETHERLANDS","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Exenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Radboud University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radboud University Medical Center \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Radboud University Medical Center \/ AstraZeneca"},{"orgOrder":0,"company":"University Hospital Gentofte, Copenhagen","sponsor":"Novo Nordisk | University of Copenhagen","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"University Hospital Gentofte, Copenhagen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University Hospital Gentofte, Copenhagen \/ Novo Nordisk | University of Copenhagen","highestDevelopmentStatusID":"9","companyTruncated":"University Hospital Gentofte, Copenhagen \/ Novo Nordisk | University of Copenhagen"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Tongji Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Pegylated Somatropin","moa":"Growth hormone receptor","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Tongji Hospital","highestDevelopmentStatusID":"9","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Tongji Hospital"},{"orgOrder":0,"company":"Transdermal Delivery Solutions Corp","sponsor":"Langford Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Transdermal Delivery Solutions Corp","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transdermal Delivery Solutions Corp \/ Langford Research Institute","highestDevelopmentStatusID":"9","companyTruncated":"Transdermal Delivery Solutions Corp \/ Langford Research Institute"},{"orgOrder":0,"company":"Jaeb Center for Health Research","sponsor":"Mannkind","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Jaeb Center for Health Research","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jaeb Center for Health Research \/ Mannkind","highestDevelopmentStatusID":"9","companyTruncated":"Jaeb Center for Health Research \/ Mannkind"},{"orgOrder":0,"company":"Biocon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Insulin Tregopil","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biocon \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Biocon \/ Undisclosed"},{"orgOrder":0,"company":"Biocon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Insulin Tregopil","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biocon \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Biocon \/ Undisclosed"},{"orgOrder":0,"company":"University of British Columbia","sponsor":"Juvenile Diabetes Research Foundation | Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"University of British Columbia","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of British Columbia \/ Juvenile Diabetes Research Foundation | Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"9","companyTruncated":"University of British Columbia \/ Juvenile Diabetes Research Foundation | Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"NovaMed Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"PAKISTAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Alpha Lipoic Acid","moa":"Lipoyl amidotransferase LIPT1, mitochondrial; Sodium-dependent multivitamin transporter; Lipoyl synthase, mitochondrial","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"NovaMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NovaMed Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"NovaMed Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Niagen Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Niagen Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Niagen Bioscience \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Niagen Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Han Xu","sponsor":"UnitedHealthcare","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Han Xu","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Han Xu \/ UnitedHealthcare","highestDevelopmentStatusID":"9","companyTruncated":"Han Xu \/ UnitedHealthcare"},{"orgOrder":0,"company":"UConn Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Amino Acid","year":"2024","type":"Inapplicable","leadProduct":"Levothyroxine Sodium","moa":"Thyroid hormone receptor","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"UConn Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UConn Health \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"UConn Health \/ Undisclosed"},{"orgOrder":0,"company":"Throne Biotechnologies","sponsor":"Hackensack Meridian Health","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Cord Blood Stem Cell","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Throne Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Throne Biotechnologies \/ Hackensack Meridian Health","highestDevelopmentStatusID":"9","companyTruncated":"Throne Biotechnologies \/ Hackensack Meridian Health"},{"orgOrder":0,"company":"Throne Biotechnologies","sponsor":"Chinese PLA General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Cord Blood Stem Cell","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Throne Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Throne Biotechnologies \/ Chinese PLA General Hospital","highestDevelopmentStatusID":"9","companyTruncated":"Throne Biotechnologies \/ Chinese PLA General Hospital"},{"orgOrder":0,"company":"Global Cell Med","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"MALAYSIA","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Adult Bone Marrow Stem Cell","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Global Cell Med","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Global Cell Med \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Global Cell Med \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AGN-282176","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Kexing Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"GB08","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Kexing Biopharm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kexing Biopharm \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Kexing Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Intralipid","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gabrail Cancer Center Research \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"9","companyTruncated":"Gabrail Cancer Center Research \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Polysan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"RUSSIA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Reamberin","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Polysan","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Polysan \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Polysan \/ Undisclosed"},{"orgOrder":0,"company":"Catalysis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Spermotrend","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Catalysis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Catalysis \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Catalysis \/ Undisclosed"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2020","type":"Partnership","leadProduct":"TOTUM\u202263","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0.070000000000000007,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Valbiotis","sponsor":"INAF","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"TOTUM\u202263","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ INAF","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ INAF"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"TOTUM\u202263","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ Undisclosed"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"TOTUM\u202263","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ Undisclosed"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"TOTUM\u202263","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Biofortis M\u00e9rieux Nutriscience | Institut Pasteur de Lille","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Totum-63","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Biofortis M\u00e9rieux Nutriscience | Institut Pasteur de Lille","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ Biofortis M\u00e9rieux Nutriscience | Institut Pasteur de Lille"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Biofortis M\u00e9rieux Nutriscience","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Totum-63","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Biofortis M\u00e9rieux Nutriscience","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ Biofortis M\u00e9rieux Nutriscience"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Laval University | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec | Valbiotis Canada inc.","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Totum-63","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Laval University | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec | Valbiotis Canada inc.","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ Laval University | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec | Valbiotis Canada inc."}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
